Role of dibromdulictol as a radlosensltlzer using two radiotherapy schedules for the management of brain secondaries

The present study analyzed 70 patients with brain secondaries from solid tumours referred to Radiotherapy and Oncology Unit, Faculty of Medicine, University of Alexandria between 1988 and 1990. Whole brain irradiation was the standard method of treatment using Co-60 teletherapy. Four treatment schedules were evaluated including SO GY/2 weeks without and with Dibromdulictol [DBD] [group I and II respectively], 30 GY/3 weeks without and [group III and IV respectively]. Good to fair tolerance was observed in 16/20 [80%], 22/15 [80%] 15/20 [75%] and 13/15 [80%] in the four treatment groups respectively, P>0.05. Performance status was not significantly improved following treatment in radiotherapy + DBD groups compared to radiotherapy alone, P>0.05. Furthermore the addition of DBD to radiotherapy was accompanied, with increased, incidence of toxicities especially haematological one9 yet the latter were tolerable and reversible. Intracranlal relapses were lower. In radiotherapy and DBD than those of radiotherapy alone, P> 0.05. On the other hand, no significant survival difference was observed among different treatment groups

clofazimin in the treatment of scleroma

Scleroma is a chronic progressive granulomatous disease predominantly affecting the mucous membrane of the upper respiratory tract, endemic in temperate and tropical zone countries, including Egypt. Many patients in early stages respond to medical treatment, while others are not responding. In these patients an antileprotic agent Clofazimine [Lamprene] was tried for a good number of cases and the therapeutic results are very promising, especially for the early stages of nasal affection